Boruzu (Bortezomib) for Lymphoma

Overview
Boruzu is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with mantle cell lymphoma, a type of non-Hodgkin lymphoma that affects the lymphatic system. Boruzu is also known by its drug name, bortezomib.

Boruzu is a proteasome inhibitor, which means it blocks certain enzymes that help break down proteins in cells. This is believed to stop cancer cells from growing and spreading, which can help destroy them.

How do I take it?
Prescribing information states that Boruzu is administered either as a subcutaneous (under the skin) injection or as an intravenous (IV) bolus injection over three to five seconds. The recommended starting dose is given at specific intervals based on a treatment cycle. The dosage and schedule may vary depending on individual patient factors. Boruzu should be administered exactly as prescribed by a healthcare provider.

Side effects
According to prescribing information, common side effects of Boruzu include nausea, diarrhea, constipation, vomiting, fatigue, peripheral neuropathy (nerve pain or numbness), thrombocytopenia (low platelet count), neutropenia (low levels of neutrophils, a type of white blood cell), anemia (low red blood cell count), leukopenia (low white blood cell count), lymphopenia (low levels of lymphocytes, another type of white blood cell), rash, fever, loss of appetite, and neuralgia (nerve pain).

Rare but serious side effects may include severe peripheral neuropathy, hypotension (low blood pressure), cardiac toxicity (heart problems including heart failure), pulmonary toxicity (lung-related complications), posterior reversible encephalopathy syndrome (a neurological condition that can cause seizures and vision loss), tumor lysis syndrome (a metabolic imbalance caused by rapid tumor breakdown), hepatic toxicity (liver damage), thrombotic microangiopathy (a disorder causing blood clots in small vessels), severe blood disorders such as thrombocytopenia and neutropenia, and potential harm to an unborn fetus.

For more information about this treatment, visit:

Label: Boruzu — Bortezomib Injection — DailyMed